2Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90. 被引量：1
3Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63:245-7. 被引量：1
4Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24:99-146. 被引量：1
5Kriegel MA, Li MO, Sanjabi S, et al. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006; 8:138-44. 被引量：1
6Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-9. 被引量：1
7Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-8. 被引量：1
8Gabrilovich 01, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103. 被引量：1
9Furlan 0, Sahnane N, Carnevali I, et al. Up-regulation of the hypoxia?inducible factor-l transcriptional pathway in colorectal carcinomas. Hum Pathol 2008; 39:1483-94. 被引量：1
10Huang CL, Liu 0, Ishikawa S, et al. Wntl overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 2008; 44: 2680-8. 被引量：1
1Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in thetumor microenvironment [ J ]. Semin Immunol ,2014,26( 1) :.38 -47. 被引量：1
2Han Z,Feng J,Hong Z,et al. Silencing of the STAT3 signaling path-way reverses the inherent and induced chemoresistance of human o-varian cancer cells [ J ]. Biochem Biophys Res Commun,2013,435(2):188 -194. 被引量：1
3Wang Y, Qu Y, Zhang XL, et al. Autocrine production of interleukin-6confers ovarian cancer cells resistance to tamoxifen via ER isoforms andSRC-1 [J].Mol Cell Endocrinol,2014,382(2) :791 -803. 被引量：1
4Voorhees PM,Chen Q, Small GW, et al. Targeted inhibition of inter-leukin-6 with CNTO 328 sensitizes pre-clinical models of multiplemyeloma to dexamethasone-mediated cell death [ J ]. Br J Haematol,2009,145(4) :481 -490. 被引量：1
5Wang J,Sharma A,Ghamande SA,et al. Serum protein profile at re-mission can accurately assess therapeutic outcomes and survival forserous ovarian cancer[ J]. PLoS One,2013 ,8(11) :e78393. 被引量：1
6Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor:impor-tance for the pro-inflammatory activities of IL-6 [ J]. Int J Biol Sci,2012,8(9) :1237 -1247. 被引量：1
7Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, et al. Serumlevels of IL-6,IL-8 and CRP as prognostic factors in epithelial ovariancancer[ J]. Eur Cytokine Netw,2013 ,24(3) : 106 - 113. 被引量：1
8Dijkgraaf EM, Welters MJ, Nortier JW, et al. Interleukin-6/interleu-kin-6 receptor pathway as a new therapy target in epithelial ovariancancer[ J]. Curr Pharm Des,2012,18(25) :3816 - 3827. 被引量：1
10Kroon P, Berry PA, Stower MJ, et al. JAK-STAT blockade inhibitstumor initiation and clonogenic recovery of prostate cancer stem-likecells [J]. Cancer Res ,2013 ,73 (16) :5288 -5298. 被引量：1
